This is genuine disruption of a $10 billion market segment.
Internal modeling is 3-5% market penetration in year one ($300m to $500m revenue). Year two is $900m.
IMO the company won’t exist at that stage, it will have been acquired.
This investment could realistically be worth multiple dollars in a couple of years time. And all we’re talking about is the value of the OSA program.
If you believe the clinical program can deliver this outcome and also believe that Joel and the team are capable of executing then just let them get on with it.
And the only way we’re going to get that result is if the company is funded. Institutional grade capital will become more important as the numbers get bigger, they can’t just rely on retail punters like us.
